Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid Tumors

NCT04975958 is registered in ClinicalTrials.gov with Adlai Nortye Biopharma Co., Ltd. as lead sponsor.

NCT NCT04975958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04975958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid Tumors
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 7, 2021
Completion date
January 24, 2025
Enrollment
47 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor